We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cost Analysis of Self-Monitoring Blood Glucose in Nonintensively Managed Type 2 Diabetes.
- Authors
Kerr, David; Duncan, Ian; Repetto, Enrico; Maroun, Rana; Wu, Alexander; Perkins, Christopher; Bergman, Gert; Giorgino, Francesco
- Abstract
OBJECTIVES: To compare health care resource utilization (HCRU) and costs between self-monitoring of blood glucose (SMBG) and continuous glucose monitoring (CGM) users in adults with nonintensively managed type 2 diabetes (T2D). STUDY DESIGN: Retrospective analysis of the MarketScan Databases. METHODS: Adults with T2D using SMBG or initiating CGM between January 2018 and March 2019 were eligible for inclusion. Inclusion criteria were (1) 2 consecutive claims for T2D or 1 claim for T2D and a claim for glucose-lowering therapy, (2) at least 1 pharmacy claim for SMBG strips or CGM sensors, and (3) continuous enrollment for 1 year before and after the index date. Individuals with evidence of CGM in the preindex period, pregnancy, use of rapid-acting insulin or glucagon, type 1 diabetes, gestational diabetes, or secondary diabetes at any time during the study period were excluded. SMBG and CGM patients were matched using propensity score, and all-cause HCRU and costs during a 1-year period were compared. RESULTS: A total of 3498 patients were included in each matched cohort. The per-patient per-year (PPPY) all-cause cost was $20,542 in CGM users vs $19,349 in SMBG users (P < .001). The PPPY cost of glucose-lowering medication was $6312 in CGM users vs $5606 in SMBG users (P < .001). No significant differences in the number of emergency department visits or hospitalizations were observed, but CGM users had more all-cause outpatient visits and office visits with an endocrinologist. CONCLUSIONS: In adults with nonintensively managed T2D, SMBG appears to be less costly than CGM and is associated with lower pharmacy costs.
- Subjects
ENDOCRINOLOGISTS; SCIENTIFIC observation; BLOOD sugar monitoring; RETROSPECTIVE studies; HYPOGLYCEMIC agents; MEDICAL care use; TYPE 2 diabetes; COST analysis; RESEARCH funding; DESCRIPTIVE statistics; MEDICAL appointments; CONTINUOUS glucose monitoring; DISEASE management; OUTPATIENT services in hospitals; ADULTS; MIDDLE age
- Publication
American Journal of Managed Care, 2023, Vol 29, Issue 12, p670
- ISSN
1088-0224
- Publication type
Article
- DOI
10.37765/ajmc.2023.89422